Beth A. Davison

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

John R. Teerlink, Gad Cotter, Beth A. Davison et al. · The Lancet · 2012 · 896 citations

Heart Failure, Cardiac Anaesthesia, Cardiogenic Shock +10

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

Alexandre Mebazaa, Beth A. Davison, Ovidiu Chioncel et al. · The Lancet · 2022 · 882 citations · Full text

Heart Failure, Structural Heart Disease, Cardiovascular Disease +8

The Causes, Treatment, and Outcome of Acute Heart Failure in 1006 Africans From 9 Countries

Albertino Damasceno, Bongani M. Mayosi, Mahmoud U. Sani et al. · Archives of Internal Medicine · 2012 · 511 citations

Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure?

Marco Metra, Beth A. Davison, Luca Bettari et al. · Circulation Heart Failure · 2011 · 467 citations

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program

Marco Metra, Gad Cotter, Beth A. Davison et al. · Journal of the American College of Cardiology · 2012 · 423 citations · Full text

Heart Failure, Stress, Medicine +10